InvestorsHub Logo
Followers 7
Posts 6123
Boards Moderated 3
Alias Born 06/27/2018

Re: None

Saturday, 06/17/2023 11:55:45 AM

Saturday, June 17, 2023 11:55:45 AM

Post# of 1530
Bruce your additional two more year plan sounds about right. They need to have some results from all the INDs they’re planning to file. That will take some time for sure. I suspect if they begin filing at the end of the year we should see some results in the second half of next year and then possibly some finished phases in the following year pending how low long the trials are. So great thought on your part. I agree. Price may go up slowly based on people’s anticipations of what’s to come for results. I’m glad you were able to understand the collaboration part of that editorial I posted. I was trying to explain to you what was happening in my own words but unfortunately I’m an idiot and that editorial did a much better job explaining their potential strategy. I like the “build to own” concept. It’s the best way to go. It’s the second part of the strategy that could take some additional years to accomplish. In the end there are only a few drugs showing progress through development phase. Remember the deal is based on having a new drug at the end. This would mean that we definitely have a wait on our hands. Every drug they have is minimum two years out or more from commercialization. It is what it is. Sucks but very true. The worst however will be behind us come August. It will be like a fresh new start. The great thing about recessions, pharma companies thrive in them. One thing we know for sure about being in pharma is that they can play with the numbers and matter, atoms and molecules have zero tangible value until the day the results show that they do. Lol. Good times. What a country!!! I look forward to another couple years of fun and games. Happy trails karate boy. Choo Choo. Cuckoo Penny
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.